Reading and Resources

Epilepsy Foundation: https://www.epilepsy.com/programs/family-services
Epilepsy Alliance America: https://www.epilepsyallianceamerica.org/programs-services/support-groups/
Local foundations: https://www.epilepsy.com/local
Grinspoon P. Cannabidiol (CBD): What we know and what we don’t. Harvard Health Publishing, 2024. https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476
Meissner H, Cascella M. Cannabidiol (CBD). StatPearls. Last updated May 7, 2024. https://www.ncbi.nlm.nih.gov/books/NBK556048/
SAMHSA Advisory. Cannabidiol (CBD) – potential harms, side effects, and unknowns, 2023. https://store.samhsa.gov/sites/default/files/pep22-06-04-003.pdf
Substance Abuse and Mental Health Services Administration (SAMHSA). Cannabidiol (CBD) – potential harms, side effects, and unknowns, 2023. https://www.samhsa.gov/resource/ebp/advisory-cbd-potential-harms-side-effect-unknowns

Castillo-Arellano J, Canseco-Alba A, Cutler SJ, et al. The polypharmacological effects of cannabidiol. Molecules. 2023;28:3271.
Gabarin A, Yarmolinsky L, Budovsky A, et al. Cannabis as a source of approved drugs: A new look at an old problem. Molecules. 2023;28:7686.
Ghosh S, Sinha JK, Ghosh S, et al. A comprehensive review of emerging trends and innovative therapies in epilepsy management. Brain Sci. 2023;13:1305.
Nguyen C, Moeller KE, McGuire M, et al. Consumer perception, knowledge, and uses of cannabidiol. Ment Health Clin. 2023;13:217-224.
O’Sullivan SE, Jensen SS, Nikolajsen NG, et al. The therapeutic potential of purified cannabidiol. J Cannabis Res. 2023;5:21.
Odieka AE, Obuzor GU, Oyedeji OO, et al. The medicinal natural products of Cannabis sativa : A review. Molecules. 2022;27:1689.
Sharma P, Holland A, Sheikh T, et al. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. PEC Innov. 2022:1:100044.
Singh K, Bhushan B, Chanchal DP, et al. Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: A comprehensive review. Behav Neurol. 2023;2023:8825358.
Szaflarski M, McGoldrick P, Currens L, et al. Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists. Epilepsy Behav. 2020:109:107102.

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers